24/7 Market News Snapshot 08 July, 2025 – ProKidney Corp. Class A Ordinary Shares (NASDAQ:PROK)

July 8, 2025

DENVER, Colo., 08 July, 2025 (www.247marketnews.com) – (NASDAQ:PROK) are discussed in this article.
ProKidney Corp. has experienced a significant boost in market activity, with its Class A Ordinary Shares (PROK) recently surging by nearly 99% to $1.205 in pre-market trading, following a closing price of $0.607 the previous day. This remarkable increase is attributed to heightened investor interest, evidenced by a robust trading volume of 13.83 million shares. The surge reflects strong confidence in ProKidney’s innovative advancements within the healthcare sector, suggesting a promising outlook as traders anticipate the company’s potential for further growth.

The excitement around ProKidney is amplified by the positive topline results from its pivotal Phase 2 clinical trial, REGEN-007, which evaluated the efficacy of rilparencel for patients with chronic kidney disease (CKD) and diabetes. The trial showcased impressive findings, particularly in Group 1, where patients receiving two injections of rilparencel experienced a striking 78% reduction in the annual decline of their estimated glomerular filtration rate (eGFR), improving from a decline of -5.8 mL/min/1.73m² to -1.3 mL/min/1.73m² after treatment. Additionally, Group 2 demonstrated a 50% improvement in eGFR slope following a single injection, indicating a potential response to the dosage administered.

Dr. Bruce Culleton, the CEO of ProKidney, expressed optimism about these results, especially as they align with the ongoing Phase 3 PROACT 1 study, which adopts a similar dosing regimen as the REGEN-007 trial. Notably, 63% of Group 1 participants meet the key inclusion criteria for the advanced study, further validating rilparencel’s efficacy. No serious adverse events associated with the treatment were reported, maintaining a favorable safety profile.

ProKidney is preparing to present the comprehensive findings from the REGEN-007 trial at the forthcoming American Society of Nephrology 2025 Kidney Week. Furthermore, with an FDA Type B meeting on the horizon, the company aims to leverage eGFR slope as a surrogate endpoint to facilitate expedited approval processes for this critical therapy, aiming to address the urgent needs of CKD patients.

Related news for (PROK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.